Despite the importance of metastatic clear-cell renal cell carcinoma, studies on its economic burden in daily practice are sparse. The mean cost of illness of 224 French patients who started their first-line treatment with a targeted therapy was estimated at V71,185 ± 52,683. Five explanatory factors were identified, among them time of disease control for the metastatic first-line treatment ‡6 months. Background: Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse. The purpose of this retrospective study was to evaluate cost of illness for 224 patients with mccRCC included in the cohort published by Thiery-Vuillemin et al (Factors influencing overall survival for patients with metastatic clear-cell renal cellcarcinoma in daily practice. Clin Genitourin Cancer 2018; 16:e297-305), and then to determine the explanatory factors of cost of illness. Patients and Methods: The study was performed from the French Public Healthcare System perspective with lifetime horizon. Only direct medical costs were included. Multiple linear regression was used to search for explanatory factors of cost of illness. The robustness of results was assessed. Results: The mean cost of illness was estimated at V71,185 AE 52,683. Outpatient/inpatient treatment and hospitalization represented 76.0% and 19.7% of this cost, respectively. After adjustment, 5 explanatory factors were identified: time of disease control for the metastatic first-line treatment !6 months, number of lines of treatment >2, nephrectomy at metastatic stage, lack of metastases at presentation, and age at metastatic diagnosis younger than 65 years. Individually, they increased cost of illness by 128%, 95%, 53%, 53%, and 23%, respectively. Conclusion: Although it is difficult to transpose our economic evaluation results to those obtained in other countries, it should be noted that our findings were consistent with them and robust. To our knowledge, our study was the first to accurately identify explanatory factors of cost of illness. Identifying them could enable us to predict the budgetary effect on a regional level of managing patients who began their first-line treatment with a targeted therapy.
Introduction
Kidney cancer accounts for 3.4% of all newly diagnosed cancers, with an overall estimate of 115,174 cases, causing 48,991 deaths (5.0%) in Europe for the year 2012. 1 It is the third most frequent urologic cancer after prostate and bladder cancers. 1 Among various histologic entities of kidney cancers, clear-cell carcinoma is the most common accounting for approximately 70% of renal-cell carcinomas (RCCs). 2 To date, 9 targeted therapies (through inhibition 1 of angiogenesis or the mammalian target of rapamycin pathway) have been evaluated in randomized, controlled phase III clinical trials in patients with metastatic RCC, and they have been approved by regulatory authorities in Europe. [3] [4] [5] [6] [7] [8] [9] [10] [11] Large randomized studies have shown significant benefit with targeted therapies, which has been confirmed in various cohorts. [12] [13] [14] These targeted therapies have transformed the treatment of metastatic clear-cell RCC (mccRCC) and have largely outperformed cytokines as the first-line standard of care. [14] [15] [16] [17] However, clinical and economic studies in daily practice are sparse. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] A previous retrospective multicenter study was conducted to assess the effectiveness of targeted therapies in real-life settings. 28 All patients with histologically confirmed mccRCC who received targeted therapies in first-line treatment were included. Three prognostic factors influencing overall survival were identified in first-line treatment: Memorial Sloan Kettering Cancer Center (MSKCC) favorable and intermediate risks, metastasectomy, and lack of lymph node metastasis. In second-line treatment, 3 different prognostic factors predicted long survival: toxicity for firstline treatment, time of disease control in first-line treatment, and MSKCC favorable and intermediate risks. These real-life data not only confirmed the positive effect of targeted therapies in the mccRCC setting, but also highlighted the importance of considering many factors to better estimate patient prognosis. Antineoplastic drugs have had a major and growing effect on health insurance expenditures. In France in 2015, antineoplastic drug expenditure for inpatients reached V1696 million, with targeted therapies representing more than 54% of this figure (V923 million). 29 In comparison, antineoplastic drug expenditure for outpatients, reimbursed by the general fund-which covers 85% of the French population-reached V1646 million (ie, 8.6% of overall drug expenditure for outpatients) and targeted therapies represented V885 million. 29, 30 In 2015, 5.1% and 4.4% of antineoplastic drug expenditure for outpatient treatment were respectively associated with everolimus and sunitinib, both being used to treat patients with mccRCC. 29 In the context of rational decision-making in health care, the economic evaluation (EE) of health care products has become a necessity. One of the major challenges is to provide cost-effectiveness data that are relevant to daily practices and might be required to optimize consumption of health care resources. Decision-making for coverage and reimbursement of new drugs is being increasingly supported by EE in many countries including Australia, Canada, and the United Kingdom. 31, 32 Furthermore, it is essential to estimate the economic burden of cancer and its management. However, despite the importance of mccRCC, data concerning its economic burden are few. Thus, the purpose of this retrospective study was to evaluate the cost of illness for 224 patients with mccRCC included in the cohort published by Thiery-Vuillemin et al, 28 and then to determine the explanatory factors of cost of illness.
Patients and Methods

Patient Population and Treatment
From January 2007 to March 2015, all consecutive patients with histologically confirmed mccRCC who started their first-line treatment with a targeted therapy in 3 main oncology treatment sites of the Institut Régional Fédératif du Cancer de Franche-Comté were included in the analysis. 28 Each anticancer drug was given until disease progression, toxicity, or death and was routinely administered according to guidelines and the summary of product characteristics. Some patients might have received drugs as part of a clinical trial; in that case, drug was given following the clinical study protocol.
Cost of Illness Study
This EE was performed from the French Public Healthcare System perspective. Only direct medical costs, from the start of metastatic first-line treatment until death from any cause or to last follow-up for survivors (lifetime horizon), were included in our analysis (ie, costs related to outpatient and inpatient treatment, hospitalization, outpatient consultations, and health care travel). Minor costs and costs considered to be independent of the treatment were not taken into account (such as premedication, outpatient treatment of adverse events). Nor were indirect medical and intangible costs. Costs are expressed in Euros (V; reference year 2015). All of these cost items were collected by reviewing each patient's medical and pharmaceutical records, completed by the French hospital discharge system for hospitalization data.
Inpatient and Outpatient Treatment
For reimbursed drugs administered in-hospital (bevacizumab, temsirolimus) and ambulatory (axitinib, everolimus, pazopanib, sorafenib, sunitinib, cytokines, and interferon) settings, we determined the exact number of milligrams per prescription and per patient and then multiplied this quantity by the purchase price of each drug. Unit prices of drugs were obtained from wholesale price lists from our hospital and from official tariffs for outpatient treatment.
Hospitalization
We identified each hospitalization for nephrectomy, anticancer drug administration, serious adverse event management, radiotherapy, metastasectomy, and best supportive care. Hospital resource costs were on the basis of the French public DiagnosisRelated Group database, which is used to fund each hospital stay and does not include expensive drugs such as bevacizumab and temsirolimus (http://atih.sante.fr). All resources were therefore included for each hospital with the exception of these expensive drugs. For instance, the Diagnosis-Related Group for chemotherapy is estimated at V410.67.
Outpatient Consultations
An outpatient consultation was performed every month for each patient (V28, according to the French Public Healthcare System) (http://ameli.fr).
Health Care Travel
Health care travel costs were estimated for each patient on the basis of the total number of hospital admissions and the number of outpatient consultations. Patient traveling costs were on the basis of 1 return trip via light medical vehicle per hospital admission or outpatient consultation, using the distance from home to hospital, according to the French Public Healthcare System (http://ameli.fr).
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Base Case and Sensitivity Analyses
Because direct medical costs were measured over a period exceeding 1 year for most patients, an annual discount rate was applied at a 4% annual rate according to recommendations of the department of Economics and Public Health Assessment of the French Haute Autorité de Santé. 33 The robustness of the cost of illness study (ie, the base-case result), was assessed through a series of deterministic 1-way sensitivity analyses. First, the anticancer drugs are the most important cost driver of cost of illness; thus, the cost of each reimbursed anticancer drug was reduced by 30%, but also increased by 30% to take into account the potential advent of generic anticancer drugs onto the European market in future years as well as intracountry price variability. Second, an annual discount rate of 0% and 5% were used instead of 4% to take into account uncertainty related to the basic methodological choice and transferability of results.
Statistical Analysis and Determination of the Explanatory Factors of Cost of Illness
Continuous variables were described as mean AE SD and range, and qualitative variables as size and percentage. The Wilcoxon rank sum test (ManneWhitney U test) or the KruskaleWallis test was used to compare continuous variables. Association between quantitative variables was measured on the Spearman rank order correlation, nonparametric measure of association on the basis of the ranks of data values (Spearman correlation coefficient [q], P).
Multiple linear regression was used to search for explanatory factors of cost of illness for patients with mccRCC (patient-related variables, mccRCC-related variables, and treatment-related variables). To determine which variables were candidates for explanatory factors of cost of illness in multiple linear regression, their association with cost of illness was previously explored in a univariate way using the ManneWhitney U test and the Spearman rank order correlation, like the correlation between candidate variables. All variables with P < .15 entered into the multiple linear regression. The data were tested for the assumption of normality for the variable of cost of illness using the ShapiroeWilk test. If the distribution is found to be skewed, this might lead to problems with statistical estimation such as heteroscedasticity in the model. Thus, the natural logarithm of cost of illness was used as the dependent variable for further analyses. Because the dependent variable was log-transformed, the coefficient estimates are semielasticities for which coefficient interpretation requires some care. Thus, for a dichotomous explanatory variable, such as MSKCC risk group (favorable ¼ 1 and intermediate/poor ¼ 0), the coefficient estimate represents the factor by which cost would be higher or lower for the favorable risk as opposed to the intermediate/poor risk. By exponentiating the estimated coefficient and subtracting 1, it is possible to interpret the result as a percentage change from the reference group. Using the delta method, we estimated and reported the standard error associated with the estimated coefficient for the switching status variable (explanatory variable). 33, 34 All tests were 2-tailed and significant at an a threshold of 5% (P).
Statistical analysis was performed with SAS software version 9.4 (SAS Institute Inc, Cary, NC).
Several variables were then studied to determine their effect on cost of illness. 
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The robustness of the base-case model was assessed through a series of deterministic 1-way sensitivity analyses, the same as for the cost of illness study.
Results
Cost of Illness Study
The mean cost of illness of 224 patients with mccRCC was estimated at V71,185 AE 52,683 with a range from V1235 to V263,405 (Table 1) . Interestingly, outpatient/inpatient treatment and hospitalization represented 76.0% and 19.7% of this cost, respectively. The mean cost of first-line treatment was estimated at V39,843 AE 36,253 (ie, 56.0% of the cost of illness; Table 2 ). The deterministic 1-way sensitivity analysis confirms the robustness of these results, with the economic effect of the cost of reimbursed anticancer drugs (Table 3) .
Explanatory Factors of Cost of Illness
Results of the univariate analysis are summarized in Table 4 . Seven potential explanatory factors were significantly associated with higher cost of illness: MSKCC prognostic risk at metastatic diagnosis (P < .0001), time of disease control for the metastatic first-line treatment (P < .0001), number of metastatic lines of treatment (P < .0001), metastasectomy (P ¼ .003), metastases at presentation (P ¼ .02), nephrectomy at metastatic stage (P ¼ .08), and age at metastatic diagnosis (P ¼ .10).
After adjustment, multiple linear regression with log-transformed cost of illness as the dependent variables showed significant associations between time of disease control for the metastatic first-line treatment !6 months, number of lines of treatment >2, nephrectomy at metastatic stage, lack of metastases at presentation, age at metastatic diagnosis younger than 65 years, and cost of illness (Table 5 ). Individually, they increased cost of illness by 128% (AE 22%), 95% (AE19%), 53% (AE19%), 53% (AE17%), and 23% (AE12%), respectively, explaining up to 47% of cost of illness variability. Thus, the extent of cost of illness can range from V15,465 (lack of explanatory factors) to V198,670 (all explanatory factors).
Discussion
Despite the importance of mccRCC, studies on its economic burden are sparse. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Most of them were conducted before 2011
and before targeted therapies appeared on the market. [18] [19] [20] [21] [22] However, targeted therapies for mccRCC have brought new hope and new challenges, considerably expanding the number of treatment options for this indication. Because we have come to question the clinical and economic effect of systematically/routinely using these targeted therapies for patients with mccRCC, we decided to assess their effectiveness and cost of illness. 28 Thus, all patients with mccRCC treated over an 8-year period in 3 main oncology treatment centers of our Franche-Comté region were included in this retrospective study. We have estimated a mean cost of illness of V71,185 AE 52,683, to investigate it against mean follow-up time after treatment initiation estimated at 25.6 AE 23.6 months (range, 0.3-111.1; ie, approximately V2,780 per patient per month), from the payer's perspective. Indirect and intangible medical costs were not taken into account and costs for loss of productivity were not included. Because of this, the cost of illness might have been underestimated. Nevertheless, it seems unlikely because of the mean age of patients at diagnosis of metastasis (67 AE 11 years). The largest cost driver of cost of illness was inpatient and outpatient anticancer treatment (76% of cost of illness). The second largest cost driver was hospital stays (20% of cost of illness). The cost of first-line treatment represented 56% of the cost of illness. Costs are expressed in Euros.
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Few EEs conducted in Europe and North America have estimated the economic burden of mccRCC for patients treated with targeted therapies. [23] [24] [25] [26] [27] In France, in 2013, Maroun et al assessed the economic burden among patients with mccRCC treated with targeted therapies from first-line of treatment to the last follow-up or death, from a hospital perspective, at V22,318 (year 2013). 23 Only 16% (against 63% in our study) of patients had received at least 1 administration of bevacizumab or temsirolimus; this can explain the difference with our results taking into account only hospital costs (approximately V30,000). Four years later, in 2017, Maroun et al assessed direct medical costs from the payer's perspective among patients with mccRCC treated in first-line with targeted therapies, from treatment initiation until the last follow-up or death. 24 Patient characteristics (age at metastatic diagnosis, sex, 
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and sites of metastases) were similar to those of our patient cohort, except for MSKCC risk group, which was unknown. Direct medical costs were estimated at V5,546 (ie, year 2016) per patient per month and treatment costs reached V2,327 per patient per month.
In comparison with our study, supplementary costs (ie, laboratory and imaging) were included which, again, might explain the difference with our results (V71,185 with a follow-up of 25.6 months or V2780 per patient per month). The first and second cost drivers were cost of treatment (in-and outpatient) and hospitalization, representing 46% and 40% of total cost, respectively. We identified these same cost drivers. Differences in terms of patient distribution among MSKCC risk group can account for the discrepancy in the results of the 2 studies. Although it is difficult to transfer our EE results to those obtained in other countries, using the same inclusion and exclusion criteria, perspective, and lifetime horizon, it should be noted that our findings were consistent with them. [25] [26] [27] Thus, a Dutch study published in 2017 by De Groot et al estimated mean cost of illness at V65,620 AE 11,031 (year 2014). Supplementary costs (only health care travel) in our study can explain the observed difference. 25 A Canadian study published in 2016 by Nazha et al estimated the mean treatment cost of the first 3 lines of treatment (taking into account only drug acquisition and hospitalization for administration) with targeted therapy at $100,078 (ie, V83,629, year 2016) from the payer's perspective. 26 It is not surprising to find treatment as the first cost driver, because previous EEs identified treatment as the main cost driver for overall mccRCC burden. 24, 27 Thus, for example, Choueiri et al performed a retrospective review of patients treated with an angiogenesis inhibitor in first-line treatment in 2 tertiary oncology centers in the United States. 27 They concluded that first-line treatment cost (ie, year 2008) for patients treated with sunitinib, sorafenib, and bevacizumab represented 71%, 74%, and 90% of cost of illness, respectively. This cost included out-and inpatient treatment, hospitalization, outpatient consultations, and health care travel. It should be noted that sensitivity analysis showed robustness of results. Indeed, knowing that treatment is the main cost driver, variation in the cost of treatment has a direct effect on overall cost. Thus, robustness of results makes it possible to minimize the effect of intracountry price variability over time, taking into account the potential advent of generic anticancer drugs on the market in the years to come.
Not surprisingly, the cost of first-line treatment is the highest compared with other lines of treatment, correlated to the duration of first-line treatment. Indeed, increasing overall survival brings about an increase in the cost of treatment. Moreover, this result was expected because nephrectomy is recommended in mccRCC treatment. 35, 36 Metastasectomy also increased first-line cost, because it was performed for 43 of 54 patients as firstline treatment. These results are similar to those of international cohorts and in agreement with standard mccRCC treatment. 26, 37 Thus, a Canadian study by Nazha et al showed a lower median cost according to the line of treatment ($55,986, $27,328, and $16,764 (year 2016) in first-, second-, and thirdline treatment, respectively).
26
Our results underscore the originality and the strength of our study on the determination of explanatory factors of the economic burden of mccRCC. Additionally, to our knowledge, our study was the first to accurately identify these explanatory factors. The results with high external validity, but low internal validity, identified 5 explanatory factors: time of disease control for the metastatic firstline treatment !6 months (increasing cost of illness by 128%), number of lines of treatment >2 (95%), nephrectomy at metastatic stage (53%), lack of metastases at presentation (53%), and age at metastatic diagnosis younger than 65 years (23%). Two factors, time of disease control >6 months and lack of metastases at presentation, have already been identified as prognostic factors of overall survival in the study by Thiery-Vuillemin et al. 28 Indeed, improving overall survival could increase the duration of treatment and therefore the cost of illness. Likewise, nephrectomy influences overall survival, and consequently the cost of illness. 38, 39 Interestingly, MSKCC prognostic risk was not related to the cost of illness, although it is the main prognostic factor of overall survival in the study by Thiery-Vuillemin et al. 
Conclusion
Identifying explanatory factors could enable us to develop a dynamic model of the economic burden of mccRCC. Such a model could, in turn, predict the budgetary effect on a regional level of managing patients who began their first-line treatment with a targeted therapy (ie, Franche-Comté). The findings could then perhaps be extrapolated on the national level, from the French health care perspective. Additionally, the model could predict different profiles of patients and enable us to compare their therapeutic strategies. Although this model explains the cost drivers of mccRCC, it does not take into account the notion of cost-effectiveness. The perspective of this study was to create a longitudinal model including time effect (through the line of treatment). This model will allow us to conduct an economic analysis to identify the best treatment sequence in patients treated at Franche-Comté region. With the advent of immunotherapy on the market and its effect on overall survival, another analysis will be performed to determine its economic effect on the management of patients with mccRCC.
Clinical Practice Points
Despite the importance of mccRCC, studies evaluating its economic burden are sparse. Most of them were conducted before 2011 and before targeted therapies appeared on the market. Targeted therapies for mccRCC have brought new hope and new challenges, considerably expanding the number of treatment options for this indication in daily practice, and then the burden of mccRCC. On the basis of a cohort including 224 consecutive French patients with histologically confirmed mccRCC who started their first-line treatment with a targeted therapy, the mean cost of illness was estimated at V71,185 AE 52,683. Five explanatory factors identified: time of disease control for the metastatic first-line treatment !6 months, number of lines of treatment >2, nephrectomy at metastatic stage, lack of metastases at presentation, and age at metastatic diagnosis younger than 65 years. These data might help physicians in daily practice to better understand the cost of illness of mccRCC before the advent of immunotherapy.
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